Jun 2026 (Q2 FY26) — Aug 5, 2026
BioCryst Q2 FY26 — Strong ORLADEYO Performance & Strategic Shift to External Innovation
Read the full callBioCryst (BCRX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
BioCryst earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 218 | +33.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 45.1 | +26.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 78.4 | +1441.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$7.79 −2.87% · −$0.23
Performance +14.4% 1Y
1Y: $6.81 on 15 Oct 2025 → $7.79. High $11.11 (8 Jul 2026), low $6.24 (5 Feb 2026).
- Previous close
- $8.02
- 52-week range
- $6.24 – $11.11
- One year
- +15.92%
Overview
- Symbol
- BCRX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
BioCryst earnings calls (BCRX)
Financials
What the filings say
Net profit, year on year: +1442% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 132 | 146 | 163 | 159 | 407 | 156 | 218 |
| Expenses | 109 | 136 | 124 | 134 | 130 | 146 | 858 | 120 |
| Operating profit | 8 | -5 | 21 | 30 | 30 | 260 | -702 | 98 |
| Operating margin | 6.6% | −3.4% | 14.6% | 18.2% | 18.6% | 64.0% | −448.6% | 45.1% |
| Other income | -21 | -21 | -20 | -23 | -17 | -12 | -19 | -19 |
| Interest | 25 | 24 | 23 | 22 | 20 | 14 | 20 | 22 |
| Profit before tax | -13 | -26 | 1 | 6 | 12 | 248 | -721 | 79 |
| Tax rate | −4.4% | −3.1% | 95.8% | 21.6% | −6.3% | 0.9% | −0.1% | 1.4% |
| Net profit | -14 | -27 | 0 | 5 | 13 | 246 | -722 | 78 |
| EPS ($ per share) | -0.07 | — | 0 | 0.02 | 0.06 | — | -2.98 | 0.31 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Reserves | -732 | -841 | -1,023 | -1,208 | -1,455 | -1,681 | -1,770 | -1,506 |
| Total liabilities | 98 | 137 | 354 | 695 | 845 | 972 | 966 | 633 |
| Fixed assets | 9 | 7 | 7 | 9 | 9 | 8 | 8 | 9 |
| Investments | — | — | — | — | — | — | 216 | 185 |
| Total assets | 147 | 175 | 335 | 588 | 550 | 517 | 490 | 514 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -93 | -90 | -135 | -142 | -162 | -95 | -52 | 347 |
| Cash from investing | 5 | 78 | -7 | 16 | -128 | -131 | 53 | -14 |
| Cash from financing | 63 | 99 | 301 | 360 | 88 | 32 | -6 | -350 |
| Net cash flow | -25 | 87 | 159 | 233 | -201 | -194 | -6 | -15 |
| Capital expenditure | -0 | -0 | -1 | -2 | -1 | -2 | -1 | -2 |
| Free cash flow | -93 | -90 | -136 | -145 | -163 | -97 | -53 | 345 |
Insider filings
61 filings between Nov 13, 2025 and Aug 31, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$4.14M
10 sales by 4 insiders
80% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 33
- Award — granted as compensation
- 8
- Option exercise — converted options into shares
- 6
- Tax withheld — shares kept back by the company to cover tax
Also filed: 3 gifts, 1 disposition to issuer.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Barnes Alane P | — | $3.46M | May 13, 2026 |
| HEGGIE THERESA | — | $504.8K | Mar 20, 2026 |
| McKee Amy E | — | $100.3K | May 18, 2026 |
| SANDERS MACHELLE | — | $68.5K | Nov 13, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 31, 2026 | MILANO VINCENT Director | Award | 1,159 | $11.2K |
| Aug 31, 2026 | McKee Amy E Director | Award | 644 | $6.2K |
| Aug 31, 2026 | Milne Jill C. Director | Award | 1,288 | $12.5K |
| Aug 31, 2026 | Frank Steven Director | Award | 1,288 | $12.5K |
| Aug 31, 2026 | Stonehouse Jon P Director | Award | 644 | $6.2K |
| Jun 11, 2026 | LEVIN ALAN G Director | Award | 15,294 | $0 |
| Jun 11, 2026 | Stonehouse Jon P Director | Award | 15,294 | $0 |
| Jun 11, 2026 | Frank Steven Director | Award | 15,294 | $0 |
| Jun 11, 2026 | McKee Amy E Director | Award | 15,294 | $0 |
| Jun 11, 2026 | HEGGIE THERESA Director | Award | 15,294 | $0 |
| Jun 11, 2026 | SANDERS MACHELLE Director | Award | 15,294 | $0 |
| Jun 11, 2026 | Milne Jill C. Director | Award | 15,294 | $0 |
| Jun 11, 2026 | MILANO VINCENT Director | Award | 15,294 | $0 |
| Jun 11, 2026 | Galson Steven K Director | Award | 15,294 | $0 |
| May 29, 2026 | Milne Jill C. Director | Award | 1,262 | $11.2K |
| May 29, 2026 | McKee Amy E Director | Award | 631 | $5.6K |
| May 29, 2026 | Stonehouse Jon P Director | Award | 631 | $5.6K |
| May 29, 2026 | Frank Steven Director | Award | 1,262 | $11.2K |
| May 29, 2026 | MILANO VINCENT Director | Award | 1,122 | $10.0K |
| May 18, 2026 | McKee Amy E Director | Sale | 11,180 | $100.3K |
| May 13, 2026 | Barnes Alane P Chief Legal Officer | Sale 10b5-1 plan | 62,500 | $596.3K |
| May 13, 2026 | Barnes Alane P Chief Legal Officer | Option exercise 10b5-1 plan | 62,500 | $315.0K |
| Apr 6, 2026 | Menon Sandeep Chief R&D Officer | Award | 205,150 | $0 |
| Mar 20, 2026 | HEGGIE THERESA Director | Sale | 49,933 | $504.8K |
| Mar 20, 2026 | HEGGIE THERESA Director | Option exercise | 49,933 | $314.6K |
| Mar 16, 2026 | Barnes Alane P Chief Legal Officer | Sale 10b5-1 plan | 150,000 | $1.37M |
| Mar 16, 2026 | Barnes Alane P Chief Legal Officer | Option exercise 10b5-1 plan | 150,000 | $826.5K |
| Mar 2, 2026 | Stonehouse Jon P Director | Disposition to issuer 10b5-1 plan | 305,995 | $2.64M |
| Mar 2, 2026 | Stonehouse Jon P Director | Option exercise 10b5-1 plan | 305,995 | $985.3K |
| Feb 27, 2026 | Milne Jill C. Director | Award | 528 | $4.6K |
| Feb 27, 2026 | McKee Amy E Director | Award | 642 | $5.6K |
| Feb 27, 2026 | MILANO VINCENT Director | Award | 848 | $7.4K |
| Feb 27, 2026 | Stonehouse Jon P Director | Award 10b5-1 plan | 421 | $3.7K |
| Feb 27, 2026 | Frank Steven Director | Award | 1,285 | $11.2K |
| Jan 23, 2026 | Milne Jill C. Director | Award | 12,272 | $0 |
| Jan 23, 2026 | Milne Jill C. Director | Award | 2,582 | — |
| Dec 22, 2025 | Gayer Charles K President and CCO | Option exercise | 10,091 | $50.9K |
| Dec 22, 2025 | Gayer Charles K President and CCO | Option exercise | 14,142 | $45.5K |
| Dec 22, 2025 | Barnes Alane P Chief Legal Officer | Sale 10b5-1 plan | 21,773 | $166.6K |
| Dec 22, 2025 | Gayer Charles K President and CCO | Option exercise | 50,000 | $275.5K |
| Dec 19, 2025 | Gayer Charles K President and CCO | Tax withheld | 11,477 | $85.0K |
| Dec 19, 2025 | Stonehouse Jon P Chief Executive Officer | Tax withheld | 61,793 | $457.9K |
| Dec 19, 2025 | Barnes Alane P Chief Legal Officer | Tax withheld 10b5-1 plan | 16,902 | $125.2K |
| Dec 18, 2025 | Stonehouse Jon P Chief Executive Officer | Gift | 10,000 | $0 |
| Dec 18, 2025 | Stonehouse Jon P Chief Executive Officer | Gift | 10,000 | $0 |
| Dec 18, 2025 | Stonehouse Jon P Chief Executive Officer | Gift | 20,000 | $0 |
| Dec 17, 2025 | Gayer Charles K President and CCO | Award | 471,000 | $0 |
| Dec 17, 2025 | Barnes Alane P Chief Legal Officer | Award | 121,700 | $0 |
| Dec 17, 2025 | Ghias Babar Chief Financial Officer | Award | 121,700 | $0 |
| Dec 15, 2025 | Barnes Alane P Chief Legal Officer | Sale 10b5-1 plan | 21,210 | $162.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for BIOCRYST PHARMACEUTICALS INC
Free account. Everything above stays public.
Write why you follow BIOCRYST PHARMACEUTICALS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading